EA
PTGX icon

Evolution Advisers’s Protagonist Therapeutics PTGX Stock Holding History

Evolution Advisers’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+5
New +$522 ﹤0.01% 735

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Evolution Advisers's PTGX Position: Q2 2026 in Review

Evolution Advisers opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 5 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #735 among its holdings.

342 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Evolution Advisers held 5 shares of Protagonist Therapeutics worth $0 as of Q2 2026.
  • Protagonist Therapeutics was a new Evolution Advisers position in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Evolution Advisers's portfolio in Q2 2026, its #735 holding.
  • 342 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Evolution Advisers's 13F filing for Q2 2026, filed 31 Jul 2026.